Glesatinib (hydrochloride)
- Product Name
- Glesatinib (hydrochloride)
- CAS No.
- 1123838-51-6
- Chemical Name
- Glesatinib (hydrochloride)
- Synonyms
- CS-2642;Glesatinib HCl;MGCD-265 HYDROCHLORIDE;Glesatinib (hydrochloride);Glesatinib (hydrochloride)(MGCD265 hydrochloride)
- CBNumber
- CB93121101
- Molecular Formula
- C31H28ClF2N5O3S2
- Formula Weight
- 656.16
- MOL File
- 1123838-51-6.mol
Glesatinib (hydrochloride) Property
- storage temp.
- Store at -20°C
- solubility
- DMSO : ≥ 28 mg/mL (42.67 mM)
- form
- Solid
- color
- Off-white to pink
N-Bromosuccinimide Price
- Product number
- CS-5530
- Product name
- Glesatinib(hydrochloride)
- Purity
- 98.25%
- Packaging
- 1mg
- Price
- $120
- Updated
- 2021/12/16
- Product number
- CS-5530
- Product name
- Glesatinib(hydrochloride)
- Purity
- 98.25%
- Packaging
- 5mg
- Price
- $320
- Updated
- 2021/12/16
- Product number
- CS-5530
- Product name
- Glesatinib(hydrochloride)
- Purity
- 98.25%
- Packaging
- 10mg
- Price
- $450
- Updated
- 2021/12/16
- Product number
- orb611465
- Product name
- Glesatinib hydrochloride
- Packaging
- 5mg
- Price
- $569.5
- Updated
- 2021/12/16
- Product number
- orb611465
- Product name
- Glesatinib hydrochloride
- Packaging
- 10mg
- Price
- $615.4
- Updated
- 2021/12/16
Glesatinib (hydrochloride) Chemical Properties,Usage,Production
Description
Glesatinib HCl is a novel potent MET/SMO dual inhibitor.
Uses
Glesatinib hydrochloride (MGCD265 hydrochloride) is an orally active, potent MET/SMO dual inhibitor. Glesatinib hydrochloride, a tyrosine kinase inhibitor, antagonizes P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC)[1][2].
in vivo
Glesatinib hydrochloride (MGCD265 hydrochloride; 15 mg/kg/day; orally; 40 weeks) causes a significant decrease in tumor size[1].
| Animal Model: | 4?6-week old female balb/c athymic (nu/nu) mice with HCC827 NSCLC tumor xenografts[1] |
| Dosage: | 15 mg/kg |
| Administration: | Orally; daily; 40 weeks |
| Result: | Caused a significant decrease in tumor size. |
References
[1] Morgillo F, et al. Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer. J Med Chem. 2017 Sep 14;60(17):7447-7458. DOI:10.1021/acs.jmedchem.7b00794
[2] Cui Q, et al. Glesatinib, a c-MET/SMO Dual Inhibitor, Antagonizes P-glycoprotein Mediated MultidrugResistance in Cancer Cells. Front Oncol. 2019 Apr 25;9:313. DOI:10.3389/fonc.2019.00313
Glesatinib (hydrochloride) Preparation Products And Raw materials
Raw materials
Preparation Products
Glesatinib (hydrochloride) Suppliers
- Tel
- 021-58950125
- Fax
- (86) 21-58955996
- info@chemexpress.com
- Country
- China
- ProdList
- 7552
- Advantage
- 61
- Tel
- 021-58955995
- Fax
- 609-228-5909
- sales@medchemexpress.cn
- Country
- United States
- ProdList
- 4861
- Advantage
- 58
- Tel
- 028-81700200 18116577057
- Fax
- 028-81705658
- 3003855609@qq.com
- Country
- China
- ProdList
- 7778
- Advantage
- 56
- Tel
- 021-52996696，15000506266 15000506266
- Fax
- +86-21-52996696
- Country
- China
- ProdList
- 4757
- Advantage
- 55
- Tel
- 571-89925085
- Fax
- 0086-571-89925065
- sales@amadischem.com
- Country
- China
- ProdList
- 131957
- Advantage
- 58
- Tel
- +1-800-259-7612
- Fax
- +1-800-259-7612
- info@musechem.com
- Country
- United States
- ProdList
- 4660
- Advantage
- 60
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Country
- United States
- ProdList
- 32435
- Advantage
- 58
- Tel
- +1-708-310-1919 +1-13798911105
- Fax
- 708-557-7486
- sales@invivochem.cn
- Country
- United States
- ProdList
- 6391
- Advantage
- 58
- Tel
- 86-571-88216897,88216896 13588875226
- Fax
- 86-571-88216895
- sales@hzclap.com
- Country
- CHINA
- ProdList
- 6312
- Advantage
- 58
- Tel
- +1 (732)236-3202
- sales@cckinase.com
- Country
- United States
- ProdList
- 2738
- Advantage
- 58